Valneva reports nine-month 2023 financial results and provides corporate updates

Product sales of €106.1 million, an increase of 42.6% compared to the first nine months of 2022 ixiaro® and dukoral® sales benefited from a continued recovery of the travel industry total revenues of €111.8 million in the first nine months of 2023 cash position of €171.3 million as of september 30, 2023 includes $50 million of the $100 million available following upsize of credit facility with leading u.s. healthcare funds deerfield and orbimed in august 20231 includes a significant payment made to pfizer in the third quarter of 2023 related to the companies' phase 3 lyme disease study “valor” chikungunya: progressing towards potential licensure of the world's first chikungunya vaccine biologic license application (bla) currently under priority review by the u.s. food and drug administration (fda) with a pdufa date at the end of november new drug submission (nds) under review by health canada marketing authorization application (maa) submitted to the european medicines agency (ema) in october 20232; accelerated assessment granted by ema's committee for medicinal products for human use (chmp). updated 2023 financial guidance reflects lower r&d expenditure expected total revenues and other income between €220 million and €260 million, including: €130 million to €150 million of product sales €90 million to €110 million of other income (assuming a sale of the priority review voucher received upon a potential approval of vla1553 before year-end) expected r&d expenses now between €60 million and €70 million (previously between €70 million and €90 million); mainly driven by lower than anticipated costs related to the closeout of the covid-19 activities financial information (unaudited results, consolidated per ifrs)         € in million nine months ending september 30,   2023 2022 total revenues 111.8 249.9 product sales 106.1 74.4 net loss (69.3) (99.1) adjusted ebitda3 (46.0) (38.0) cash                  171.3                  261.0 saint-herblain (france), november 9, 2023 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today reported consolidated financial results for the first nine months of the year, ended september 30, 2023.
VALN Ratings Summary
VALN Quant Ranking